NASDAQ:MEDP

Medpace (MEDP) Stock Price, News & Analysis

Medpace logo
$626.05 -7.93 (-1.25%)
As of 10:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Medpace Stock (NASDAQ:MEDP)

Advanced

Key Stats

Today's Range
$623.77
▼
$633.87
50-Day Range
$587.52
▼
$692.68
52-Week Range
$373.00
▼
$693.97
Volume
23,419 shs
Average Volume
321,146 shs
Market Capitalization
$17.51 billion
P/E Ratio
34.80
Dividend Yield
N/A
Price Target
$649.27
Consensus Rating
Hold

Company Overview

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas.

Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance. Its work supports studies from early development through later-stage trials and regulatory submission.

The company serves clients internationally, with operations across the Americas, Europe and Asia. Medpace was founded by August Troendle, who continues to lead the company as its chief executive officer.

AI Generated. May Contain Errors.

Medpace Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

MEDP MarketRank™: 
2.670790378005 of 5 stars

Medpace scored higher than 53% of companies evaluated by MarketBeat, and ranked 438th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Medpace has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on no strong buy ratings, 3 buy ratings, 10 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Medpace is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Medpace has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Medpace's stock forecast and price target.
  • Earnings Growth

    Earnings for Medpace are expected to grow by 8.14% in the coming year, from $18.06 to $19.53 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Medpace is 35.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.10.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Medpace is 35.14, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.21.

  • Price to Earnings Growth Ratio

    Medpace has a PEG Ratio of 2.51. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Medpace has a P/B Ratio of 30.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Medpace's valuation and earnings.
  • Percentage of Shares Shorted

    6.23% of the float of Medpace has been sold short.
  • Short Interest Ratio / Days to Cover

    Medpace has a short interest ratio ("days to cover") of 3.46, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Medpace has recently decreased by 14.15%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Medpace does not currently pay a dividend.

  • Dividend Growth

    Medpace does not have a long track record of dividend growth.

  • News Sentiment

    Medpace has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Medpace this week, compared to 8 articles on an average week.
  • Search Interest

    2 people have searched for MEDP on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 5 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $174,850,299.00 in company stock.

  • Percentage Held by Insiders

    20.50% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Medpace's insider trading history.
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MEDP Stock News Headlines

Medpace Holdings, Inc. (MEDP) - What Are Analysts Saying About This Stock?
Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
See More Headlines

MEDP Stock Analysis - Frequently Asked Questions

Medpace's stock was trading at $561.65 at the beginning of the year. Since then, MEDP shares have increased by 12.9% and is now trading at $633.98.

Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings results on Wednesday, October, 21st. The company reported $4.84 earnings per share for the quarter, topping the consensus estimate of $4.44 by $0.40. The business's quarterly revenue was up 8.5% compared to the same quarter last year.
Read the conference call transcript
.

Medpace (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Top institutional shareholders of Medpace include Aberdeen Group plc (7.98%), State Street Corp (2.55%), Bessemer Group Inc. (1.01%) and Stephens Investment Management Group LLC (0.64%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Brian T Carley, Stephen P Ewald, Jesse J Geiger, Kevin M Brady, Cornelius P Mccarthy III, Fred B Davenport Jr, Robert O Kraft and Ashley M Keating.
View institutional ownership trends
.

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), PayPal (PYPL), Shopify (SHOP), Tesla (TSLA), Arista Networks (ANET) and Broadcom (AVGO).

Company Calendar

Last Earnings
10/21/2026
Today
11/20/2026
Fiscal Year End
12/31/2026
Next Earnings (Estimated)
2/08/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:MEDP
CIK
1668397
Employees
6,200
Year Founded
1992

Price Target and Rating

High Price Target
$730.00
Low Price Target
$515.00
Potential Upside/Downside
+2.4%
Consensus Rating
Hold
Rating Score (0-4)
2.23
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
$18.04
Trailing P/E Ratio
35.14
Forward P/E Ratio
32.46
P/E Growth
2.51
Net Income
$451.12 million
Net Margins
18.24%
Pretax Margin
22.09%
Return on Equity
99.76%
Return on Assets
24.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.83
Quick Ratio
0.83

Sales & Book Value

Annual Sales
$2.84 billion
Price / Sales
6.25
Cash Flow
$16.67 per share
Price / Cash Flow
38.02
Book Value
$20.91 per share
Price / Book
30.32

Miscellaneous

Outstanding Shares
27,972,000
Free Float
22,238,000
Market Cap
$17.73 billion
Optionable
Optionable
Beta
1.12

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:MEDP) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners